Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Helping Young Adults with Sickle Cell Disease Navigate Healthcare Inequities
The Department of Internal Medicine’s August 10, 2023, grand rounds, “Understanding Transition in Sickle Cell Disease” was given by Cece Calhoun, MD, MPHS, MBA, assistant professor of medicine (hematology), Yale School of Medicine, and medical director of the Sickle Cell Program at Smilow Cancer Hospital and Yale Cancer Center.
ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology
Madeline Mayday, BS, a fourth-year Experimental Pathology graduate student in the Laboratory of Diane Krause, MD, PhD, was recently awarded a 2022 National Institute of Diabetes and Digestive and Kidney Diseases Hematology Centers Program Type B Pilot and Feasibility grant
Bernard G. Forget Hematology Scholars Program Supported by Friends who Give
Mary Alice and Thomas O’Malley’s recent gift to support Yale’s Bernard G. Forget Hematology Scholars Program is rooted in multiple friendships. The couple learned about the program from their friend Alan Lebowitz, MD., who was Associate Clinical Professor of Medicine at Yale School of Medicine and is a retired Connecticut hematologist. Dr. Lebowitz, a champion of Yale Cancer Center, was also a close friend of the Scholars Program’s late namesake.
Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Department of Neurology Receives Major Grant to Evaluate Blood Thinners and Stroke Prevention
Yale School of Medicine has received a 5-year, $20 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to administer a Phase III trial measuring the effectiveness of using a blood thinner to prevent new strokes in patients who suffered brain hemorrhages and have atrial fibrillation, or irregular heartbeat.
Yale Researchers Crack the Code of a Rare, Inherited Anemia
Yale pediatrician and geneticist Patrick Gallagher, M.D., studies hereditary spherocytosis (HS), an inherited disease associated with hemolytic anemia, when red blood cells are destroyed faster than they are produced due to abnormal membranes. A novel mutation in the gene that encodes alpha-spectrin, a protein essential for normal red blood cell membranes, is responsible for many cases of recessive hereditary spherocytosis (rHS), the most severe form of the disease, reports Gallagher’s team
Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
Pediatric Hematologist Presents on Rare Leukemia
At the Hematology Research Seminar Friday, August 3, Nina Kadan-Lottick, MD, associate professor of pediatrics (hematology/oncology), presented research on a rare form of leukemia to scientists and adult oncologists, an audience of potential collaborators.
Stahl honored at 59th American Society of Hematology Annual Meeting
For the second consecutive year, Yale Cancer Center (YCC) researcher Maximilian Stahl, M.D., was awarded an American Society of Hematology (ASH) Abstract Achievement award. Besides working at YCC, Stahl is one of five Internal Medicine Traditional Residency Program Chiefs at Yale School of Medicine. He received the ASH award for his abstract titled, “The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis”. The ASH Abstract Achievement Award is a merit-based award for trainees with high-scoring annual meeting abstracts.
Yale Cancer Center Researchers Identify New T cell Subsets with Potential to Improve Cellular Therapy for Cancer
A Yale Cancer Center research team has identified that two genes, NR4A1 and ABC transporters, mark a distinct subset of quiescent T cells within human tissues, and have developed methods to mobilize them into circulation for potential application in adoptive T cell therapy of cancer.